CTRI/2021/12/038651招募中2 期
A phase II, randomized, assessor-blind, multicenter, multi-dose, placebo-controlled study assessing the safety and anti-coronavirus response of brequinar combined with dipyridamole in patients with mild to moderate SARS-CoV-2 infection.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Willing and able to provide informed consent for the trial, written, electronic, verbal, or other method deemed acceptable by the institution and IRB.
- •2.Subjects between ââ?°Â¥18 and ââ?°Â¤65 years of age.
- •3.Subjects found positive for SARS-CoV-2 either by rapid antigen test or by reverse transcription polymerase chain reaction (RT-PCR) using ICMR-validated kit.
- •Note: Test need not be repeated in those with possession of confirmed positive report but positive result test date must be ââ?°Â¤5 days of first dose of study drug.
- •4.Mild or Moderate COVID-19 as per latest updated version of CLINICAL MANAGEMENT PROTOCOL for COVID-19 (in Adults) released by Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division).
- •5.The effects of brequinar on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration.
- •6.Male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar.
- •7.At least one non-respiratory COVID-19 symptom characterized as mild to moderate by the Investigator including but not limited to fatigue, chills, fever, body aches, nasal congestion, nausea, vomiting, or other sign or symptom commonly associated with COVID-19 in the opinion of the investigator. Symptom onset must be ââ?°Â¤5 days prior to first dose. Subject must have one or more signs/symptoms present at first dose.
- •8.Willing to participate in the PK subset if at one of the identified sites.
- •9.Able to swallow capsules.
排除标准
- •1.Have an oxygen saturation of <90% while breathing ambient air.
- •2.Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject.
- •3.Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy test.
- •4.Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other agents known to cause bone marrow suppression leading to thrombocytopenia.
- •5.Ongoing treatment with aspirin and or dipyridamole, famotidine or cimetidine. Remdesivir and ivermectin are prohibited through Study Day 8. Steroids are permitted per the guidelines.
- •6.Platelets less than or equal to 125,000 cell/mm3.
- •7.Hemoglobin less than 10 gm/dL.
- •8.Absolute neutrophil count less than 1000 cells/mm3.
- •9.Renal dysfunction, i.e., creatinine clearance less than 30 mL/min.
- •10.AST or ALT more than 3 x ULN, or total bilirubin more than ULN. Gilbertââ?¬•s Syndrome is allowed.
- •11.Bleeding disorders or blood loss requiring transfusion in the six weeks preceding enrollment.
- •12.Ongoing gastrointestinal ulcer, or gastrointestinal bleeding within 6 weeks of first dose.
- •13.Chronic hepatitis B infection, active hepatitis C infection, active liver disease and/or cirrhosis per subject report.
- •14.Heart failure, current uncontrolled cardiovascular disease, including unstable angina, uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g., stroke, myocardial infarction, hospitalization due to heart failure, or revascularization procedure).
研究者
相似试验
进行中（未招募）
不适用
A phase II randomised, controlled, assessor-blind, parallel group clinical trial to demonstrate the proof of concept of an experimental pediculicide rinse and Lyclear Creme Rinse in the treatment of head lice - Study of two treatments in the eradication of head lice (25/02/2004)Head lice infestationEUCTR2004-002022-22-GBSSL International plc
进行中（未招募）
1 期
A study to test how well a new medicine called sirukumab works in patients with Severe Uncontrolled Asthmasubjects with severe, poorly controlled asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-001244-19-ESGlaxoSmithKline, S.A.175
进行中（未招募）
不适用
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ quadrivalent influenza candidate vaccine GSK2321138A (FLU D-QIV), when administered to children 18 to 47 months of age.Healthy volunteers (immunisation against influenza in male and female subjects 18 to 47 months of age inclusive).EUCTR2012-002587-27-Outside-EU/EEAGlaxoSmithKline Biologicals600
未知
2 期
A Phase II study of T-4288 in patients with community-acquired pneumoniaCommunity-acquired pneumoniaJPRN-jRCT2080222672Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.EUCTR2011-000814-21-PTBIAL INDUSTRIAL FARMACEUTICA, S.A.150